难治性肾病的治疗-根据蛋白尿机制开发的新药和老药新用  

Treatment of refractory nephrotic syndrome - novel medications and old newly used medications based on the mechanisms of proteinuria

作　　者：周国平[1] 

机构地区：[1]南京医科大学第一附属医院儿科,210029

出　　处：《中华实用儿科临床杂志》2016年第5期324-328,共5页Chinese Journal of Applied Clinical Pediatrics

基　　金：国家自然科学基金面上项目（30570863,30872804,81170661）;南京巾科技计划项目（201503003）

摘　　要：各种难治性肾病综合征即使是同一种病理类型也有非常不同的发病机制，近年来有较多报道根据机制研究开发的肾病新药（如奥法木单抗和艾库组单抗）或老药新用（如辅酶Q10、半乳糖和维A酸），或者反过来，根据其他病种的新药用于肾病有效而发现肾病的新机制。现介绍几种新的成功用于难治性肾病临床的或蛋白尿实验动物的新型药物，或新的有效老药，并简要描述主要作用机制。希望这些信息对临床肾脏科医师选择用药和肾病领域的科研人员碰撞出思维灵感，并有实用价值。Even one the same pathological type of various kinds of refractory nephrotic syndrome has great dif-ferent pathogenesis. It is more reported in recent years that new nephrotic medications （ such as Ofatumumab and Eculi- zumab） or novel utilized old medications （such as CoQ10 ,galactose and retinoic acid） used in other diseases were re- searched and developed based on the mechanisms of nephrotic syndrome ,or new mechanisms were contrarily discovered when new medications used in other diseases were effectively used in refractory nephrotic syndrome. Here, the novel medications which were successfully used in clinic patients with refractory nephrotic syndrome, or laboratory proteinuric animal models, or the old medications with new and effective actions were introduced. Their mechanisms of drug actions were also briefly described. It is hoped that these information has practical value for the medication selection by clinical nephrologist and for the collision of research idea inspiration by investigators in nephropathy research area.

关 键 词：肾病综合征 蛋白尿 药物 机制 

分 类 号：R726.9[医药卫生—儿科]